Assessment Status | Rapid Review Complete |
HTA ID | 25013 |
Drug | Ravulizumab |
Brand | Ultomiris® |
Indication | Ravulizumab (Ultomiris®) is indicated for the treatment of adult patients with neuromyelitis optica spectrum disorder who are anti-aquaporin 4 antibody positive. |
Assessment Process | |
Rapid review commissioned | 17/02/2025 |
Rapid review completed | 14/03/2025 |
Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ravulizumab compared with the current standard of care. |